Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial.
New therapies in the management of rheumatoid arthritis.
Phase II Study with Ocrelizumab Shows Significant Reduction in Disease Activity for Multiple Sclerosis Patients
Myelin oligodendrocyte glycoprotein-specific T and B cells cooperate to induce a Devic-like disease in mice.
Episode 64 with Dr. Helen Tremlett on pediatric MS and the gut microbiome
Improper Inducements
Efficacy and Safety of GTR in Comparison to Copaxone® (GATE)
Episode 71 with Dr. Brian Weinshenker on innovative clinical trials for NMO
A Study of Efficacy and Safety of Ocrelizumab in Patients with Relapse-Remitting Multiple Sclerosis
MS Research Roundup: April 23, 2014
CellCept (Product Insert)
Episode 66 with Dr. Jeremy Hobart on optimizing treatment outcomes
The Prevention of Post-Partum Relapses with Progestin and Estradiol in Multiple Sclerosis (POPART'MUS) trial: rationale, objectives and state of advancement.
Gordon Research Conference: Myelin
Episode 51 with Dr. Luke Lairson on discovery of small molecules to induce remyelination
Exclusive breastfeeding and the risk of postpartum relapses in women with multiple sclerosis.
Ocrelizumab Bests Interferon in Relapsing-Remitting MS
A network meta-analysis of randomized controlled trials for comparing the effectiveness and safety profile of treatments with marketing authorization for relapsing multiple sclerosis.
Efficacy and safety of BG-12 (dimethyl fumarate) and other disease modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison.
LINGO-1 negatively regulates myelination by oligodendrocytes.
U.S. FDA grants Breakthrough Therapy Designation for Roche’s investigational medicine ocrelizumab in primary progressive multiple sclerosis
Autoimmunity's next top models.
MS Research Roundup: February 5, 2014
Protective effect of breastfeeding in postpartum relapse rate of mothers with multiple sclerosis.
FDA Warns About CCSVI Treatment

Pages